Latest podcasts: American Society of Tropical Medcine and Hygiene, Washington DC; American Heart Association, Orlando
Archive for November, 2009
London School of Hygiene & Tropical Medicine Audio News Review, August 31st, 2007
Philippe Mayaud
Herpes Simplex Therapy Reduces HIV Activity in Co-Infected Patients
REFERENCE: N Engl J Med 2007; 356: 790-9
PHILIPPE MAYAUD, London School of Hygiene and Tropical Medicine
It is possible to reduce HIV activity in patients who are co-infected with HIV and herpes simplex type 2. Philippe Mayaud tells us about the study which showed reduced HIV concentration in the blood and vagina when co-infected patients underwent continuous treatment with anti-herpes agent valacyclovir.
PHILIPPE MAYAUD, London School of Hygiene and Tropical Medicine
It is possible to reduce HIV activity in patients who are co-infected with HIV and herpes simplex type 2. Philippe Mayaud tells us about the study which showed reduced HIV concentration in the blood and vagina when co-infected patients underwent continuous treatment with anti-herpes agent valacyclovir.
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer
Pierre Laurent-Puig
Bill Hait
REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles
PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor samples from patients with colorectal cancer gives clear prognostic information about the effectiveness of therapy with the epidermal growth factor receptor inhibitor cetuximab. This is the finding of a group from Paris reported at the American Association for Cancer Research 2007 Annual Meeting held in Los Angeles. Peter Goodwin discussed research findings with Pierre Laurent-Puig.
Bill Hait, President of the American Association for Cancer Research, commented on the findings from Paris discussed by Pierre Laurent-Puig about the value of the KRAS mutation in predicting the response of patients with metastatic colorectal cancer to therapy with cetuximab.
PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor samples from patients with colorectal cancer gives clear prognostic information about the effectiveness of therapy with the epidermal growth factor receptor inhibitor cetuximab. This is the finding of a group from Paris reported at the American Association for Cancer Research 2007 Annual Meeting held in Los Angeles. Peter Goodwin discussed research findings with Pierre Laurent-Puig.
Bill Hait, President of the American Association for Cancer Research, commented on the findings from Paris discussed by Pierre Laurent-Puig about the value of the KRAS mutation in predicting the response of patients with metastatic colorectal cancer to therapy with cetuximab.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
London School of Hygiene & Tropical Medicine Audio News Review, August 28th, 2007
Pat Doyle
Increased Miscarriage Risk in Women with Low Body Mass Index
REFERENCE: BJOG 2007 114:170
PAT DOYLE, London School of Hygiene and Tropical Medicine
Underweight women with a BMI below 18.5 have a 70 per cent increase in their risk of miscarriage according to a study published in the British Journal of Obstetrics and Gynaecology. Pat Doyle gave us the details.
PAT DOYLE, London School of Hygiene and Tropical Medicine
Underweight women with a BMI below 18.5 have a 70 per cent increase in their risk of miscarriage according to a study published in the British Journal of Obstetrics and Gynaecology. Pat Doyle gave us the details.
Gene Study Identifies Heart Disease Risk
Nilesh Samani
REFERENCE: N Engl J Med 2007; 357: 443-53
NILESH SAMANI, University of Leicester UK
Previously unrecognised DNA segments in human genes have been found to significantly increase the risk of coronary artery disease. That’s according to a publication just out in the New England Journal of Medicine. Nilesh Samani from the University of Leicester explained how this will help identify new high-risk groups and target prevention before the disease develops in at risk individuals.
NILESH SAMANI, University of Leicester UK
Previously unrecognised DNA segments in human genes have been found to significantly increase the risk of coronary artery disease. That’s according to a publication just out in the New England Journal of Medicine. Nilesh Samani from the University of Leicester explained how this will help identify new high-risk groups and target prevention before the disease develops in at risk individuals.
London School of Hygiene & Tropical Medicine Audio News Review, August 25th, 2007
David Moore
Seven-Day Low-Cost Tuberculosis Diagnosis
REFERENCE: N Engl J Med 355: 1539-50
DAVID MOORE, Imperial College, London and Lima
A new test for TB (reported in the New England Journal of Medicine) has proved more powerful, faster and yet cheaper than any alternative. David Moore explains how the Microscopic-Observation Drug-Susceptibility (MODS) Assay is highly sensitive and specific, and also yields drug susceptibility data.
DAVID MOORE, Imperial College, London and Lima
A new test for TB (reported in the New England Journal of Medicine) has proved more powerful, faster and yet cheaper than any alternative. David Moore explains how the Microscopic-Observation Drug-Susceptibility (MODS) Assay is highly sensitive and specific, and also yields drug susceptibility data.
Vaginal Progesterone Reduced Risk of Preterm Birth in Women with Short Cervix
Kypros Nicolaides
REFERENCE: N Engl J Med 2007; 357: 426-9
KYPROS NICOLAIDES, Kings College Hospital, London
The risk of giving birth prematurely was reduced among pregnant women with short cervices by treatment with vaginally administered progesterone: whether or not they had a history of preterm delivery. Investigators from London have reported in the New England Journal of Medicine that progesterone therapy significantly reduced the risk of spontaneous delivery before 34 weeks: from a one in three chance with a placebo to one in five with progesterone. Kypros Nicolaides discussed the results with Anna Lacey.
KYPROS NICOLAIDES, Kings College Hospital, London
The risk of giving birth prematurely was reduced among pregnant women with short cervices by treatment with vaginally administered progesterone: whether or not they had a history of preterm delivery. Investigators from London have reported in the New England Journal of Medicine that progesterone therapy significantly reduced the risk of spontaneous delivery before 34 weeks: from a one in three chance with a placebo to one in five with progesterone. Kypros Nicolaides discussed the results with Anna Lacey.
London School of Hygiene & Tropical Medicine Audio News
Simon Lewin
Adherence to TB Medication
PLoS Med 4(7):e238. doi:10.1371/journal.pmed.0040238
SIMON LEWIN, London School of Hygiene and Tropical Medicine
A new systematic review has shown that we don’t understand well enough the reasons for poor adherence to tuberculosis medication. Simon Lewin of the London School of Hygiene and Tropical Medicine calls for a better approach in the area.
SIMON LEWIN, London School of Hygiene and Tropical Medicine
A new systematic review has shown that we don’t understand well enough the reasons for poor adherence to tuberculosis medication. Simon Lewin of the London School of Hygiene and Tropical Medicine calls for a better approach in the area.
Virus Plus Cytokine Fight Primary and Metastatic Cancer
Paul Fisher
REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles
PAUL FISHER, Columbia University, New York
Patients with cancer could soon be treated with adenoviruses capable of infecting both primary and distant tumors, and simultaneously releasing cancer-fighting cytokines, according to Paul Fisher, who presented his group’s findings to the AACR Annual Meeting in Los Angeles. He told delegates about his group’s work in which “conditionally replication competent adenoviruses” have been used to treat animals, and how they release cytokine IL-24, which reaches primary and distant disease simultaneously through the bloodstream. During the conference he discussed his group’s latest data with Peter Goodwin, and speculated about the future potential of this approach in the clinical setting.
PAUL FISHER, Columbia University, New York
Patients with cancer could soon be treated with adenoviruses capable of infecting both primary and distant tumors, and simultaneously releasing cancer-fighting cytokines, according to Paul Fisher, who presented his group’s findings to the AACR Annual Meeting in Los Angeles. He told delegates about his group’s work in which “conditionally replication competent adenoviruses” have been used to treat animals, and how they release cytokine IL-24, which reaches primary and distant disease simultaneously through the bloodstream. During the conference he discussed his group’s latest data with Peter Goodwin, and speculated about the future potential of this approach in the clinical setting.
Earlier Interferon Reduces Disability in Patients With Multiple Sclerosis
Ludwig Kappos
REFERENCE: Lancet 2007; 370: 389-97
LUDWIG KAPPOS, University Hospital, Basel
Earlier treatment can reduce the risk of confirmed disability in patients with multiple sclerosis, according to a new study published in the Lancet. Three-year follow-up of the BENEFIT study showed favourable results among patients who began treatment with interferon beta-1b after a first event suggestive of multiple sclerosis, rather than waiting for further confirmatory events. Nicola Solomon interviewed Ludwig Kappos.
LUDWIG KAPPOS, University Hospital, Basel
Earlier treatment can reduce the risk of confirmed disability in patients with multiple sclerosis, according to a new study published in the Lancet. Three-year follow-up of the BENEFIT study showed favourable results among patients who began treatment with interferon beta-1b after a first event suggestive of multiple sclerosis, rather than waiting for further confirmatory events. Nicola Solomon interviewed Ludwig Kappos.
Cortical Grafting Or Intact Ovary Transplantation for Preserving Fertility?
Sherman Silber
REFERENCE: O-149
SHERMAN SILBER, St Luke’s Hospital, St Louis MO
A study from Missouri has shown that transplanting intact ovaries using microvascular surgical techniques is superior in the long term for restoring or preserving fertility to the simpler technique known as cortical grafting. Sarah Maxwell heard about the findings from Sherman Silber during the fertility conference held in Lyon.
SHERMAN SILBER, St Luke’s Hospital, St Louis MO
A study from Missouri has shown that transplanting intact ovaries using microvascular surgical techniques is superior in the long term for restoring or preserving fertility to the simpler technique known as cortical grafting. Sarah Maxwell heard about the findings from Sherman Silber during the fertility conference held in Lyon.
Lapraroscopic Ovarian Diathermy Or Clomifene as First Line Treatment for Polycystic Ovarian Syndrome?
Saad Amer
REFERENCE: O-148
SAAD AMER, The Derby Medical School, Nottingham University
More reassurance about the use of clomifene for treating anovulatory women with polycystic ovarian syndrome has emerged from a randomised study from Nottingham reported to the fertility conference held in Lyon. Laparoscopic ovarian diathermy, normally used as second line treatment (after clomifene), was found to be equivalent for inducing ovulation and pregnancy in a study with over sixty women. But Saad Amer explained to Sarah Maxwell why he still favours clomifene.
SAAD AMER, The Derby Medical School, Nottingham University
More reassurance about the use of clomifene for treating anovulatory women with polycystic ovarian syndrome has emerged from a randomised study from Nottingham reported to the fertility conference held in Lyon. Laparoscopic ovarian diathermy, normally used as second line treatment (after clomifene), was found to be equivalent for inducing ovulation and pregnancy in a study with over sixty women. But Saad Amer explained to Sarah Maxwell why he still favours clomifene.
Audio Journal of Medicine: Single Embryo Transfer: Just as High Live Birth Rates as Double Transfer, But Without Risks
&ot
Kersti Lundin
REFERENCE: O-004
KERSTI LUNDIN, Sahlgrenska University Hospital, Göteborg, Sweden
The same birth rates following in-vitro fertilisation can be achieved with single embryo transfer as with double transfer, according to the findings of a study from Sweden. A retrospective investigation looked at whether multiple births, and other risk factors associated with double embryo transfer, can be avoided when single transfer is used whilst still achieving the same live delivery rates. Sarah Maxwell talked with study author Kersti Lundin during the European fertility conference in Lyon.
KERSTI LUNDIN, Sahlgrenska University Hospital, Göteborg, Sweden
The same birth rates following in-vitro fertilisation can be achieved with single embryo transfer as with double transfer, according to the findings of a study from Sweden. A retrospective investigation looked at whether multiple births, and other risk factors associated with double embryo transfer, can be avoided when single transfer is used whilst still achieving the same live delivery rates. Sarah Maxwell talked with study author Kersti Lundin during the European fertility conference in Lyon.
© 2007 Audio Medica – Medical Audio News Interviews & Podcasts. 
